Skip to main content

Moxetumomab pasudotox Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 12, 2021.

For the Consumer

Applies to moxetumomab pasudotox: intravenous powder for solution

Warning

Intravenous route (Powder for Solution)

Warning: Capillary Leak Syndrome And Hemolytic Uremic SyndromeCapillary Leak Syndrome (CLS), including life-threatening cases, occurred in patients receiving moxetumomab pasudotox-tdfk. Monitor weight and blood pressure; check labs, including albumin, if CLS is suspected. Delay dosing or discontinue moxetumomab pasudotox-tdfk as recommended.Hemolytic Uremic Syndrome (HUS), including life-threatening cases, occurred in patients receiving moxetumomab pasudotox-tdfk. Monitor hemoglobin, platelet count, serum creatinine, and ensure adequate hydration. Discontinue moxetumomab pasudotox-tdfk in patients with HUS.

Side effects requiring immediate medical attention

Along with its needed effects, moxetumomab pasudotox may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking moxetumomab pasudotox:

More common

  • Back pain
  • black, tarry stools
  • blood in the urine
  • blurred vision
  • bone pain
  • chest pain or tightness
  • chills
  • confusion
  • cough
  • dizziness
  • drowsiness
  • dry mouth
  • fast or irregular heartbeat
  • feeling of warmth
  • fever
  • headache
  • increased or decreased urination
  • increased thirst
  • joint pain, stiffness, or swelling
  • loss of appetite
  • loss of consciousness
  • lower back, side, or stomach pain
  • mood or mental changes
  • muscle cramps in the hands, arms, feet, legs, or face
  • muscle pain
  • muscle spasms (tetany) or twitching seizures
  • nausea
  • nervousness
  • numbness and tingling around the mouth, fingertips, or feet
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • pounding in the ears
  • redness of the face, neck, arms, and occasionally, upper chest
  • seizures
  • slow or fast heartbeat
  • sore throat
  • stomach cramps or pain
  • swelling of the face, fingers, feet, lower legs, or ankles
  • trembling
  • tremor
  • troubled breathing
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting
  • yellow eyes or skin

Less common

Side effects not requiring immediate medical attention

Some side effects of moxetumomab pasudotox may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

  • Blindness
  • bloody eye
  • burning, dry, or itching eyes
  • decreased vision
  • discharge, excessive tearing
  • discomfort, pain, or swelling of the eye or around the eye
  • redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid

For Healthcare Professionals

Applies to moxetumomab pasudotox: intravenous powder for injection

Hematologic

Very common (10% or more): Hemoglobin decreased (43%), neutrophil count decreased (41%), platelet count decreased (21%), anemia (21%)

Common (1% to 10%): Hemolytic uremic syndrome[Ref]

Immunologic

Frequency not reported: Immunogenicity[Ref]

Local

Very common (10% or more): Infusion related reactions (e.g., chills, cough, dizziness, dyspnea, feeling hot, flushing, headache, hypertension, hypotension, infusion related reaction, myalgia, nausea, pyrexia, sinus tachycardia, tachycardia, vomiting, wheezing) (50%)[Ref]

Musculoskeletal

Very common (10% or more): Hypoalbuminemia (64%), fluid retention (63%), electrolyte abnormalities (57%), hypocalcemia (54%), hypophosphatemia (53%), hyponatremia (41%), peripheral edema (39%), hypokalemia (25%), hypomagnesemia (21%), hyperuricemia (21%)

Common (1% to 10%): Weight gain, localized edema, fluid overload, fluid retention[Ref]

Ocular

Common (1% to 10%): Blurred vision, dry eye, cataracts, ocular discomfort and/or pain, ocular swelling/periorbital edema, conjunctivitis, conjunctival hemorrhage, ocular discharge[Ref]

Hepatic

Very common (10% or more): ALT increased (65%), AST increased (55%), blood bilirubin increased (30%), GGT increased (25%)[Ref]

Respiratory

Very common (10% or more): Cough, dyspnea, wheezing

Common (1% to 10%): Pleural effusion[Ref]

Other

Very common (10% or more): Fatigue (34%), pyrexia (31%), alkaline phosphatase increased (20%), chills, feeling hot[Ref]

Nervous system

Very common (10% or more): Headache (33%), dizziness[Ref]

Renal

Very common (10% or more): Renal toxicity (e.g., acute kidney injury, renal impairment, renal failure, increased serum creatinine, proteinuria) (26%)[Ref]

Cardiovascular

Very common (10% or more): Capillary leak syndrome (34%), flushing, hypertension, hypotension, sinus tachycardia, tachycardia

Common (1% to 10%): Pericardial effusion[Ref]

Dermatologic

Very common (10% or more): Facial edema (14%), abdominal distention (13%)[Ref]

Gastrointestinal

Very common (10% or more): Nausea (35%), constipation (23%), diarrhea (21%), vomiting

Common (1% to 10%): Ascites[Ref]

Frequently asked questions

References

1. "Product Information. Lumoxiti (moxetumomab pasudotox)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.